Time and cost of administering COVID-19 mRNA vaccines in the United States. Issue 11 (2nd November 2021)

• Record Type: Journal Article
• Authors: Yarnoff, Benjamin; Bodhaine, Steven; Cohen, Ed; Buck, Philip O.
• Is Part Of: Human vaccines & immunotherapeutics. Volume 17:Issue 11(2021)
• Page Start: 3871
• Page End: 3875
• Publication Date: 2021-11-02
• Subjects: COVID-19 -- labor cost -- health economics -- mRNA vaccine -- administration time -- USA; Vaccinology; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2021.1974289
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: In early 2020, the World Health Organization (WHO) declared the coronavirus disease 2019 (COVID-19) outbreak a global pandemic. In response, two novel messenger RNA (mRNA)-based vaccines: mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) were rapidly developed. A thorough understanding of the differences in workflow requirements between the two vaccines may lead to improved efficiencies and reduced economic burden, both of which are crucial for streamlining vaccine deployment and minimizing wastage. Vaccine administration workflow costs are borne by providers and reimbursed separately from dose acquisition in the United States. Currently, mRNA-1273 and BNT162b2 are the most administered COVID-19 vaccines in the United States. In this study, US-licensed and practicing pharmacists were interviewed to collect data on differences in terms of labor costs associated with the workflows for mRNA-1273 and BNT162b2. Results suggest the cost differential for mRNA-1273 compared to BNT162b2 is −$0.82 (or −$1.01 when assuming volume equivalency). If extrapolated to even just a proportion of the remaining unvaccinated US population, this can amount to significant workflow efficiencies and lower vaccine administration costs. Further, as key differences in the vaccine workflow steps between the two vaccines would be similar in other settings/regions, these findings are likely transferable to health-care systems worldwide.